Cyclic Yamanaka Factor Reprogramming Reduced Stroke Damage in Aged Mice

This is animal research, not a human trial. According to the paper in Aging Cell (2026), the team used 30 mice aged 12 to 18 months, 16 male and 14 female. The authors' title says that partial reprogramming with Yamanaka factors reduced ischemic brain damage in aging mice. The text available to us covers the background and methods, and it stops before the results. We therefore cannot report the size of the effect or which measures changed.

Some background first. An ischemic stroke happens when blood flow to part of the brain is blocked. The authors note that about 87% of strokes are of this type. Current treatments restore blood flow, either with clot-dissolving drugs or by removing the clot mechanically. According to the paper, these can only be used within a limited window and can cause bleeding. They also do not prevent long-term nerve damage. Sudden return of blood can itself add injury.

Yamanaka factors are four proteins (Oct4, Sox2, Klf4 and c-Myc) that can push adult cells back toward a younger, stem-cell-like state. Run continuously in mice, they caused tumors called teratomas and shortened life. The authors say short, repeated bursts avoid full dedifferentiation, meaning cells losing their identity. Earlier work they cite reports benefits in muscle, liver, retina, skin and heart tissue, and in mouse models of Alzheimer's disease.

In this study, the mice carried genes that switch the four factors on when they are given the antibiotic doxycycline in drinking water. Both the engineered mice and normal littermates received doxycycline. The schedule was three days on and four days off, repeated for four weeks. Surgery followed six hours after the last dose was stopped.

The stroke was a permanent blockage of the middle cerebral artery, made by threading a filament into the vessel. Of the 30 mice, 14 had the stroke procedure and 16 had a sham operation without the filament. Brains were examined 48 hours later. The team tracked neurological deficits at 6, 24 and 48 hours using a seven-point scoring system. They also used a beam-walking test and a rope-gripping test.

There are clear limits. The study followed the mice for only two days after the stroke. Treatment began weeks before the stroke, which is not how people experience one. The stroke group was also younger (12 to 17 months) than the sham group (16 to 18 months). The authors state that the effects of brain reprogramming in elderly mice with ischemia had not been characterized before.

What to watch next

The full results on tissue damage and behavior, whether the effect holds when treatment starts after a stroke, and how the factors could be delivered safely in people.